Postmenopausal hormone therapy and its association with breast cancer
With the cessation of estrogen and progesterone at menopause, the hormone withdrawal affects various systems in the woman's body. In earlier days, menopausal hormone therapy (HT) was prescribed for primary prevention of coronary artery disease (CAD) and osteoporosis, which were thought to be be...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Journal of Mid-Life Health |
| Subjects: | |
| Online Access: | http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2020;volume=11;issue=4;spage=187;epage=195;aulast=Syal |
| _version_ | 1818446045063938048 |
|---|---|
| author | Arshi Syal Neelam Aggarwal |
| author_facet | Arshi Syal Neelam Aggarwal |
| author_sort | Arshi Syal |
| collection | DOAJ |
| description | With the cessation of estrogen and progesterone at menopause, the hormone withdrawal affects various systems in the woman's body. In earlier days, menopausal hormone therapy (HT) was prescribed for primary prevention of coronary artery disease (CAD) and osteoporosis, which were thought to be because of estrogen deprivation and epidemiologic data supported a beneficial effect of estrogen on the heart and bone. Later on, robust data from the Women's Health Initiative study comparing two HT trials demonstrated adverse outcomes in terms of excess risk of CAD, stroke, venous thromboembolism, and breast cancer. Even with risk stratification based on family history, approximately only 15% of women diagnosed with breast cancer have such a risk factor. This implies that family history will not be elicited in more than 85% of women who develop breast cancer. Literature review suggests that the prior use of conjugated equine estrogen (CEE) alone has the potential to be effective as an intervention, leading to a reduction in mortality due to breast cancer. Therefore, it is time to reevaluate the risk reduction strategies for breast cancer that are currently in practice. In terms of absolute numbers, for every 10,000 person-years of prior use of CEE alone, there would be only two fewer deaths from breast cancer and two fewer deaths secondary to its sequelae. This translates into a significant number of women in our country with a population of 1.38 billion (of which 48%, nearly 650 million, are women). |
| first_indexed | 2024-12-14T19:41:28Z |
| format | Article |
| id | doaj.art-1b90e10244f0418e95da9f41e73988a2 |
| institution | Directory Open Access Journal |
| issn | 0976-7800 0976-7819 |
| language | English |
| last_indexed | 2024-12-14T19:41:28Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Mid-Life Health |
| spelling | doaj.art-1b90e10244f0418e95da9f41e73988a22022-12-21T22:49:42ZengWolters Kluwer Medknow PublicationsJournal of Mid-Life Health0976-78000976-78192020-01-0111418719510.4103/jmh.jmh_284_20Postmenopausal hormone therapy and its association with breast cancerArshi SyalNeelam AggarwalWith the cessation of estrogen and progesterone at menopause, the hormone withdrawal affects various systems in the woman's body. In earlier days, menopausal hormone therapy (HT) was prescribed for primary prevention of coronary artery disease (CAD) and osteoporosis, which were thought to be because of estrogen deprivation and epidemiologic data supported a beneficial effect of estrogen on the heart and bone. Later on, robust data from the Women's Health Initiative study comparing two HT trials demonstrated adverse outcomes in terms of excess risk of CAD, stroke, venous thromboembolism, and breast cancer. Even with risk stratification based on family history, approximately only 15% of women diagnosed with breast cancer have such a risk factor. This implies that family history will not be elicited in more than 85% of women who develop breast cancer. Literature review suggests that the prior use of conjugated equine estrogen (CEE) alone has the potential to be effective as an intervention, leading to a reduction in mortality due to breast cancer. Therefore, it is time to reevaluate the risk reduction strategies for breast cancer that are currently in practice. In terms of absolute numbers, for every 10,000 person-years of prior use of CEE alone, there would be only two fewer deaths from breast cancer and two fewer deaths secondary to its sequelae. This translates into a significant number of women in our country with a population of 1.38 billion (of which 48%, nearly 650 million, are women).http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2020;volume=11;issue=4;spage=187;epage=195;aulast=Syalbreast cancerhormone therapymenopause |
| spellingShingle | Arshi Syal Neelam Aggarwal Postmenopausal hormone therapy and its association with breast cancer Journal of Mid-Life Health breast cancer hormone therapy menopause |
| title | Postmenopausal hormone therapy and its association with breast cancer |
| title_full | Postmenopausal hormone therapy and its association with breast cancer |
| title_fullStr | Postmenopausal hormone therapy and its association with breast cancer |
| title_full_unstemmed | Postmenopausal hormone therapy and its association with breast cancer |
| title_short | Postmenopausal hormone therapy and its association with breast cancer |
| title_sort | postmenopausal hormone therapy and its association with breast cancer |
| topic | breast cancer hormone therapy menopause |
| url | http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2020;volume=11;issue=4;spage=187;epage=195;aulast=Syal |
| work_keys_str_mv | AT arshisyal postmenopausalhormonetherapyanditsassociationwithbreastcancer AT neelamaggarwal postmenopausalhormonetherapyanditsassociationwithbreastcancer |